Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lacroix

Showing results (301-310 of 308) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 308 results.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
Nature Communications|July 2, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesI Garberis, V Gaury, C Saillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variantsM Messaoudene, T P Mourikis, J Michels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic CancerKatelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Pageof 31

Showing results (301-310 of 308) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 308 results.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
Nature Communications|July 2, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesI Garberis, V Gaury, C Saillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variantsM Messaoudene, T P Mourikis, J Michels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic CancerKatelyn T Byrne, Courtney B Betts, Rosemarie Mick, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survivalY Wang, D Drubay, S F Jonas, et al.
Pageof 31